Nesher Pharmaceuticals, an arm of Zydus Pharmaceuticals USA has received its first Abbreviated New Drug Application (ANDA) approval from the US FDA to market Dextroamphetamine IR Tabs. The drug which falls in the CNS stimulant segment and is the first product to be developed by the R&D team at Nesher. The drug will be produced at the manufacturing facility based at St. Louis, Missouri, USA. The estimated sales for Dextroamphetamine IR Tabs is US $ 40.6 million.
Company Profile : Cadila Healthcare Ltd
Leave a Reply